COMP <GO>

INDP vs NGNE // ALTMAN Z-SCORE & DEBT/EQUITY

Indaptus Therapeutics Inc. (NASDAQ) VS. Neurogene Inc. (NASDAQ) • 15-METRIC TALLY: INDP 3 — NGNE 0

■ METRIC PARITY

LAST: $3.24 (-7.43%) • MKT CAP: $537.5M

balance-sheet

—

LAST: $26.67 (+0.23%) • MKT CAP: $532.5M

balance-sheet

12.76

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDP VS. NGNE) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	INDP	NGNE	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	-35.00%	0.00	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	-2.89%	-13.59%	+10.70	INDP	/fcf-yield <GO>
Operating Margin	—	—	—	TIE	/operating-margins <GO>
Net Profit Margin	—	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE	—	12.76	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	2/9	2/9	0.00	TIE	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	59.5	48.0	+11.50	INDP	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$537.5M	$532.5M	$5.0M	INDP	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	INDP REV	NGNE REV	INDP GROSS %	NGNE GROSS %	INDP FCF	NGNE FCF
FY 2025	$55.5M	$289.3M	—	—	-$14.8M	-$78.4M
FY 2024	$43.0M	$925.0K	—	—	-$12.3M	-$71.4M
FY 2023	$45.9M	$155.6M	—	—	-$13.4M	-$51.4M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

INDP // BETA —

NGNE // BETA —